Startseite
Forum
Fragen
Suchen
Über Uns
Registrieren
Login
FAQ
Suchen
Foren-Übersicht
->
Neuzeit
Antwort schreiben
Benutzername
(du bist
nicht
eingeloggt!)
Titel
Nachrichtentext
Smilies
Weitere Smilies ansehen
Schriftfarbe:
Standard
Dunkelrot
Rot
Orange
Braun
Gelb
Grün
Oliv
Cyan
Blau
Dunkelblau
Indigo
Violett
Weiß
Schwarz
Schriftgröße:
Schriftgröße
Winzig
Klein
Normal
Groß
Riesig
Tags schließen
[quote="pysong"]Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio across the hospital, including in the operating room. PerClot has a global commercial presence with sales in more than 35 countries worldwide. It is not currently cleared for sale in the United States.To get more news about [url=https://www.rusuntacmed.com/medical/hemorrhage-control/]hemostatic granules[/url], you can visit rusuntacmed.com official website. The addition of PerClot further enhances our ability to optimize patient care by addressing a broad range of intraoperative bleeding with both active and passive hemostatic solutions, helping surgeons to use the right product for the right bleed,” said Wil Boren, president of Baxter’s Advanced Surgery business. “PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.” Addressing intraoperative bleeding is important in preventing blood transfusions and major complications for patients, as well as reducing the total cost of care. A blood management strategy that includes effective hemostasis is especially critical in today’s environment, given current worldwide shortages of blood donations and products due to the ongoing COVID-19 pandemic. A recent retrospective analysis found that implementing a framework that incorporates patient factors and a bleeding severity tool, such as Baxter’s Validated Intraoperative Bleeding Scale (VIBe SCALE), can support optimal hemostatic product selection.[1] A polysaccharide hemostatic powder can be used as an adjunctive hemostat to facilitate control of bleeding from capillary, venous or arteriolar vessels to address low-grade intraoperative bleeding.[2] PerClot is composed of plant starch that is modified to create an adhesive hemostatic powder. It is used as an adjunctive hemostatic device to control bleeding during multiple open and laparoscopic surgical procedures, including gynecologic, general, cardiovascular and urology. PerClot rapidly absorbs water from blood to produce a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue. CryoLife recently completed a multicenter, randomized controlled clinical trial of more than 300 patients intended to support an application for U.S. Food and Drug Administration (FDA) clearance. The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder). Indications: PerClot Polysaccharide Hemostatic System (PHS) is indicated for use in surgical procedures (except neurological and ophthalmic) or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical. Contraindications: Do not apply PerClot PHS into blood vessels as potential for embolization and death may exist. PerClot PHS is contraindicated in patients who are sensitive to starch or starch-derived materials. Warnings: PerClot PHS is not intended as a substitute for good surgical practice, and in particular, the proper use of conventional procedures (such as ligature) for hemostasis.[/quote]
Optionen
HTML ist
an
BBCode
ist
an
Smilies sind
an
HTML in diesem Beitrag deaktivieren
BBCode in diesem Beitrag deaktivieren
Smilies in diesem Beitrag deaktivieren
Spamschutz
Text aus Bild eingeben
Alle Zeiten sind GMT + 1 Stunde
Gehe zu:
Forum auswählen
Themenbereiche
----------------
Altertum
Antike
Mittelalter
Neuzeit
Sonstiges
Sonstiges
----------------
Materialien und Klausuren
Off-Topic
Ankündigungen
Thema-Überblick
Autor
Nachricht
wrex
Verfasst am: 15. Apr 2024 11:27
Titel: value
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
Ñайт
tuchkas
Ñайт
Ñайт
wrex
Verfasst am: 11. Jul 2023 03:18
Titel: value
Brea
800
Bett
Bett
Musi
Wind
Dard
Flor
Kill
Leig
Mich
Fisk
Warn
Fisk
Past
Tesc
Take
Vera
Alsa
Kath
Kick
Gast
Tesc
Keny
Tesc
Drop
Keny
Glis
Vipe
Garn
Stev
Inte
Appe
Clyd
Rabb
Glob
SHAR
Korr
Lady
Myth
Patr
Alfr
Acca
Ness
Leon
Cera
Payo
Rath
Roge
Line
Dani
KISS
Ella
Geor
Barb
Barb
Musi
Rabi
Lycr
Intr
Samb
XVII
silv
Macb
Niki
thes
CryT
Cata
Fyod
Wind
Plus
Disn
Marc
Roun
SURF
Powe
Swar
Enid
Fran
Happ
XVII
Wind
diam
Zone
Zone
Ital
Ecoc
Rond
Zone
Fred
Ench
Zone
Robe
Will
Feel
Miyo
Jame
Dolb
Chui
Jose
Quen
Lili
Robe
Digi
Will
Will
Side
Will
Fyod
Iren
Arth
Dupi
QBBJ
very
John
Wind
WGPy
Fiat
PCIe
Lawi
Stud
Elec
Live
Book
Spit
Davi
Brad
Ameb
Neri
Mist
Wood
MONT
Stan
Sams
Blue
Roya
Firs
Orle
Vali
Happ
Clit
ProS
Jing
Vtec
Wind
Wind
Dyan
Phot
Mole
Bosc
frie
Ruby
Twis
Jewe
King
Only
Davi
XVII
Easy
Jewe
Rock
wwwb
Ocea
Euwe
XVII
Stef
Fran
Nico
Kare
Acad
Vern
Vasi
Rich
Jeff
Said
Hung
Stra
Vasi
Film
Dolb
MPEG
Geor
Roge
Dolb
Mobi
Enjo
Lead
Penn
Kate
Neil
Mich
Myst
Dean
Ford
Jose
Trai
Jame
Mitt
John
Iced
Dies
Lewi
Camb
Stan
Micr
PCIe
PCIe
PCIe
mail
Heav
Mich
Gree
Pamp
beat
Fion
Nick
Rene
Gott
Mill
Dont
tuchkas
OZON
Rake
pysong
Verfasst am: 27. Feb 2023 07:20
Titel: Baxter Announces Acquisition of PerClot Polysaccharide Hemos
Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio
Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio across the hospital, including in the operating room. PerClot has a global commercial presence with sales in more than 35 countries worldwide. It is not currently cleared for sale in the United States.To get more news about
hemostatic granules
, you can visit rusuntacmed.com official website.
The addition of PerClot further enhances our ability to optimize patient care by addressing a broad range of intraoperative bleeding with both active and passive hemostatic solutions, helping surgeons to use the right product for the right bleed,” said Wil Boren, president of Baxter’s Advanced Surgery business. “PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.”
Addressing intraoperative bleeding is important in preventing blood transfusions and major complications for patients, as well as reducing the total cost of care. A blood management strategy that includes effective hemostasis is especially critical in today’s environment, given current worldwide shortages of blood donations and products due to the ongoing COVID-19 pandemic. A recent retrospective analysis found that implementing a framework that incorporates patient factors and a bleeding severity tool, such as Baxter’s Validated Intraoperative Bleeding Scale (VIBe SCALE), can support optimal hemostatic product selection.[1]
A polysaccharide hemostatic powder can be used as an adjunctive hemostat to facilitate control of bleeding from capillary, venous or arteriolar vessels to address low-grade intraoperative bleeding.[2] PerClot is composed of plant starch that is modified to create an adhesive hemostatic powder. It is used as an adjunctive hemostatic device to control bleeding during multiple open and laparoscopic surgical procedures, including gynecologic, general, cardiovascular and urology. PerClot rapidly absorbs water from blood to produce a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.
CryoLife recently completed a multicenter, randomized controlled clinical trial of more than 300 patients intended to support an application for U.S. Food and Drug Administration (FDA) clearance. The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).
Indications: PerClot Polysaccharide Hemostatic System (PHS) is indicated for use in surgical procedures (except neurological and ophthalmic) or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.
Contraindications: Do not apply PerClot PHS into blood vessels as potential for embolization and death may exist. PerClot PHS is contraindicated in patients who are sensitive to starch or starch-derived materials.
Warnings: PerClot PHS is not intended as a substitute for good surgical practice, and in particular, the proper use of conventional procedures (such as ligature) for hemostasis.